Key Stats for Doximity Stock
- 52-Week Range: $21 to $77
- Current Price: $25
- Street Mean Target: $38
- Street High Target: $55
- TIKR Model Target (Dec. 2030): $34
What Happened?
Doximity (DOCS), the digital platform serving more than 85% of all U.S. physicians, absorbed a 30% single-session selloff in February after its Q4 revenue guidance landed below what Wall Street had priced in.
The company projected fiscal Q4 revenue of $143 million to $144 million, representing 4% growth at the midpoint, below the $148 million consensus estimate, with adjusted EBITDA guided at $63.5 million to $64.5 million against expectations of $68.8 million.
The miss was not a business problem but a timing problem: pharmaceutical clients delayed upfront budget commitments at year-end after 16 of the top 20 pharma companies signed Most Favored Nation agreements with the White House, leaving annual media plans incomplete as December closed.
The evidence that the delay was temporary rather than structural arrived immediately: January pharma bookings growth was the best the company had recorded since going public.
On the Q3 earnings call, CEO Jeff Tangney stated that “revenue will build sequentially from F4Q as DOCS secures outstanding renewals, upsells and new engagements,” pointing to unreleased pharma budgets, an active mid-year upsell season, and a commercial AI product entering the market later in calendar 2026 as the three engines of re-acceleration.
The AI angle is not aspirational: in Doximity’s first full quarter after acquiring Pathway AI in August, more than 300,000 physicians used the company’s AI products, over 100 major health systems cleared privacy and AI governance committees and purchased access, and DocsGPT outperformed its nearest competitor at twice the rate in a 1,300-physician head-to-head trial.
Wall Street’s Take on DOCS Stock
The selloff created a disconnect: the near-term guide was genuinely soft, but Doximity’s underlying platform metrics, EBITDA economics, and AI expansion trajectory all continued to compound at rates the guided Q4 number does not reflect.
DOCS’ EBITDA reached $356 million for fiscal year 2026, growing 13.4% year-over-year against a backdrop of record physician engagement and accelerating AI adoption, with consensus projecting forward EBITDA of around $370 million in fiscal 2027 as pharma budgets normalize and the commercial AI product begins contributing.
Eleven analysts carry buy ratings on Doximity stock, five hold outperform ratings, and seven remain at hold, with a mean price target of $37.77 against the current price of $25, representing implied upside above 50%, with Wall Street specifically watching for evidence that mid-year upsell commitments absorb the deferred Q4 demand.
The $55 high-end target reflects a scenario where AI monetization accelerates faster than guided and the digital health advertising market expands above the 5% consensus growth assumption, while the $25 low-end target prices in a prolonged pharma budget freeze with no material AI revenue contribution in fiscal 2027.
Priced at roughly 16x forward EBITDA against a business that grew EBITDA at a 36% CAGR over the prior three fiscal years and sustains above 55% EBITDA margins, Doximity stock appears undervalued relative to a platform whose physician network depth, AI infrastructure, and recurring pharma client relationships have not materially deteriorated.
Tangney’s statement that “we have no revenue in our forecast for our AI products right now” sets a clean baseline: any commercial AI traction in the back half of calendar 2026 is pure upside to the current consensus, not already embedded in guidance.
If pharma clients continue to defer budget releases through the summer and MFN policy uncertainty persists beyond Q4, the mid-year upsell season could disappoint, compressing the re-acceleration thesis.
The specific number to watch at the May 13 fiscal Q4 earnings call is bookings growth and whether management upgrades its double-digit exit growth rate commentary into formal guidance language.
What Does the Valuation Model Say?
TIKR’s mid-case model prices Doximity stock at $33.89, anchored to a revenue CAGR of around 5% through fiscal 2030 and a net income margin holding near 45.5%, assumptions that embed no meaningful contribution from the commercial AI products Tangney has committed to bringing to market in calendar 2026.
Against a current price of $25, the gap between where DOCS trades and where TIKR’s model prices a conservative base case makes Doximity stock appear undervalued, with a forward multiple that assigns near-zero value to the AI monetization optionality the company has already demonstrated at scale with 300,000 active physician users.
The central tension for Doximity stock is whether the pharma budget delay is a one-quarter anomaly or the beginning of a structurally lower-growth digital health advertising environment.
What Has to Go Right
- Mid-year upsell bookings absorb the deferred Q4 demand, extending the January bookings record (best growth since IPO) through Q2 and Q3 of calendar 2026
- Commercial AI products enter the market on schedule and tap into pharma innovation and paid search budgets, a segment representing 55% of digital health marketing spend per eMarketer
- The 100 health systems currently running Doximity’s AI suite expand usage across their 180,000 credentialed clinicians, deepening platform stickiness and the data moat for next-generation AI training
- EBITDA margins sustain above 50% even as AI infrastructure investment scales, consistent with management’s stated floor and the 60% EBITDA margin delivered in Q3 while absorbing the Pathway AI integration
What Could Go Wrong
- Pharma MFN agreements and D2C marketing restrictions create a multi-quarter freeze in annual planning cycles, preventing the budget release management is forecasting for mid-2026
- AI monetization is delayed beyond fiscal 2027, leaving DOCS growing at the market’s 5% base rate without any incremental contribution from its 300,000 physician AI user base
- Gross margin erosion from AI infrastructure investment, already down approximately 200 basis points year-over-year to 91% in Q3, accelerates as usage scales and compresses EBITDA margins toward the 50% floor
- CFO transition risk: Anna Bryson’s resignation effective April 13, with Chief Accounting Officer Siddharth Sitaram named interim principal financial officer, introduces execution uncertainty entering the most consequential year in the company’s AI pivot
Should You Invest in Doximity, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up DOCS stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Doximity, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze DOCS stock on TIKR for Free →
